The mechanism of action of a new synthetic steroid, 6-dehydro-16-methylene-hydrocortisone (STC 407), which has been found useful in the treatment of Cushing’s syndrome due to adrenal hyperplasia, was studied in the rat. After treatment of normal rats with STC 407 for 11–14 days, the CRF content of the median eminence of the hypothalamus (SME), the concentration of ACTH in the anterior pituitary, the wet weight of the adrenal glands/ 100 g b.w., the adrenal corticosterone concentration/100 mg, and the plasma corticosterone level were significantly decreased. After treatment of adrenalectomized rats with STC 407 for 4 days, the concentration of ACTH in the pituitary was increased, but there was no appreciable change in CRF activity in the SME. Plasma levels of ACTH, which were elevated after adrenalectomy, decreased to undetectable levels after 4 days’ treatment with 400 µ g/100 g b.w. daily. Treatment of adrenalectomized rats with this steroid for 13 days considerably reduced CRF activity in the SME, and significantly raised the pituitary ACTH content. These results indicate that STC 407 suppresses both the release and the synthesis of ACTH by the pituitary in normal rats, this effect being mediated at least in part by a reduction in hypothalamic CRF activity. In adrenalectomized rats, the predominant effect of this steroid seems to be suppression of release of ACTH by the pituitary.

Keywords:
6-Dehydro-16-methylene-hydrocortisone, Adrenalectomy, CRF, ACTH, Corticosterone
© 1970 S. Karger AG, Basel
1970
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.